Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers.
Corcoran RB, Settleman J, Engelman JA. Corcoran RB, et al. Oncotarget. 2011 Apr;2(4):336-46. doi: 10.18632/oncotarget.262. Oncotarget. 2011. PMID: 21505228 Free PMC article. Review.
The PI3K pathway as drug target in human cancer.
Courtney KD, Corcoran RB, Engelman JA. Courtney KD, et al. Among authors: corcoran rb. J Clin Oncol. 2010 Feb 20;28(6):1075-83. doi: 10.1200/JCO.2009.25.3641. Epub 2010 Jan 19. J Clin Oncol. 2010. PMID: 20085938 Free PMC article. Review.
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. Corcoran RB, et al. Sci Signal. 2010 Nov 23;3(149):ra84. doi: 10.1126/scisignal.2001148. Sci Signal. 2010. PMID: 21098728 Free PMC article.
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Ebi H, et al. Among authors: corcoran rb. J Clin Invest. 2011 Nov;121(11):4311-21. doi: 10.1172/JCI57909. Epub 2011 Oct 10. J Clin Invest. 2011. PMID: 21985784 Free PMC article.
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA. Faber AC, et al. Among authors: corcoran rb. Cancer Discov. 2011 Sep;1(4):352-65. doi: 10.1158/2159-8290.CD-11-0106. Epub 2011 Jul 22. Cancer Discov. 2011. PMID: 22145099 Free PMC article.
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. Corcoran RB, et al. Cancer Discov. 2012 Mar;2(3):227-35. doi: 10.1158/2159-8290.CD-11-0341. Epub 2012 Jan 16. Cancer Discov. 2012. PMID: 22448344 Free PMC article.
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.
Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, Engelman JA. Corcoran RB, et al. Cancer Cell. 2013 Jan 14;23(1):121-8. doi: 10.1016/j.ccr.2012.11.007. Epub 2012 Dec 13. Cancer Cell. 2013. PMID: 23245996 Free PMC article.
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. Corcoran RB, et al. Sci Transl Med. 2013 Jul 31;5(196):196ra98. doi: 10.1126/scitranslmed.3005753. Sci Transl Med. 2013. PMID: 23903755 Free PMC article.
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA. Faber AC, et al. Among authors: corcoran rb. Cancer Discov. 2014 Jan;4(1):42-52. doi: 10.1158/2159-8290.CD-13-0315. Epub 2013 Oct 25. Cancer Discov. 2014. PMID: 24163374 Free PMC article.
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.
Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA. Zhu Z, et al. Among authors: corcoran rb. Cancer Discov. 2014 Apr;4(4):452-65. doi: 10.1158/2159-8290.CD-13-0646. Epub 2014 Jan 20. Cancer Discov. 2014. PMID: 24444711 Free PMC article.
70 results
Jump to page